NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.
about
Rituximab for thyroid-associated ophthalmopathyRituximab for thyroid-associated ophthalmopathyDaclizumab therapy for multiple sclerosisAnti B-cell therapy against refractory thrombocytopenia in SLE and MCTD patients: long-term follow-up and review of the literature.Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathyImmune mediated diseases and immune modulation in the neurocritical care unitHuman Cytokine Genetic Variants Associated With HBsAg Reverse Seroconversion in Rituximab-Treated Non-Hodgkin Lymphoma Patients.Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.Drug delivery technologies for autoimmune disease.B cells and progressive multifocal leukoencephalopathy: search for the missing linkLymphocytes as Biomarkers of Therapeutic Response in Rheumatic Autoimmune Diseases, Is It a Realistic Goal?Rituximab in Minimal Change Disease: Mechanisms of Action and Hypotheses for Future Studies.Relationship between NK Cell Activation and Clinical Response in Rheumatoid Arthritis Treated with Rituximab.The role of different subsets of regulatory T cells in immunopathogenesis of rheumatoid arthritisNK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab.Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.Rituximab-induced interleukin-15 reduction associated with clinical improvement in rheumatoid arthritis.Daclizumab Therapy for Multiple Sclerosis.
P2860
Q24202845-7B34EDA2-7145-48B7-A2FC-763CD0A87948Q24235160-42CCE038-E6F5-455B-AAC7-6F513902755AQ27022517-6BF6FA60-D597-4AA1-918D-956D92384ED3Q33407247-8152DCF1-62C9-4035-A1BA-52C2E3ADE022Q33624477-6EED7CE5-8275-4AB6-A509-CB97DE058BD8Q35729575-2A9DEBCF-75FD-4848-8309-FA4DF9D2A765Q36822761-95C80566-A7DC-4025-95B8-A804F10572FCQ37343849-2E9FF8F6-AB49-490F-9EF1-219312326F3BQ37801381-ABE57777-F9DB-4F5F-9971-2115A2B1303FQ38515349-BE5944C2-D409-4AC7-A33F-221D08730F51Q38676903-8712287A-5E23-4275-A27D-D1840982F7E3Q38679589-3AE03D01-44AB-41D1-B356-F24694693D01Q39530138-967937AF-E84E-425E-93E0-44E153B39748Q41582338-8D89EAF1-CB6B-4B0C-93F5-CEFE0D9A28E9Q42020570-C544A90C-E258-4F3B-8392-57CDA57C2A0DQ46377533-7683AEAA-3265-42A2-98A9-DFA6C2B42BEBQ50872769-4D9BD390-DCE4-472A-9242-32B30836873FQ52319805-93A61B70-4733-4EE2-AA26-2CE47A779060
P2860
NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@ast
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@en
type
label
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@ast
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@en
prefLabel
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@ast
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@en
P2093
P1476
NK and NKT cell dynamics after ...... osus and rheumatoid arthritis.
@en
P2093
Daniel A Athanazio
Eliana A G Reis
Isabella Lima
Jorge Clarencio S Andrade
Lúcio M Barbosa
Mittermayer B Santiago
Natália Oliveira e Silva
Ronden N Jesus
P2888
P304
P356
10.1007/S00296-008-0719-0
P577
2008-09-28T00:00:00Z
P5875
P6179
1041931193